Drug shortage
Extended Release · Teva Pharmaceuticals USA, Inc.
FDA drug shortage · Current · updated Apr 7, 2025
Key facts
| Generic name | Extended Release, Methylphenidate Hydrochloride Tablet |
|---|---|
| Proprietary name | Methylphenidate Hydrochloride Extended-Release Tablets, Usp Cii |
| Company | Teva Pharmaceuticals USA, Inc. |
| Presentation | Methylphenidate Hydrochloride Extended-Release Tablets, USP CII, Tablet, Extended Release, 27 mg (NDC 62037-734-01) |
| Dosage form | Extended Release, Tablet |
| Strength | 27 mg |
| Status | Current |
| Reason for shortage | Demand increase for the drug |
| Therapeutic category | Psychiatry |
| Package NDCs | 62037-734-01 |
| First posted | Jul 26, 2023 |
| Last updated | Apr 7, 2025 |
At a glance
- 1–9 Package NDCs affected
- 100–999 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: